Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ORMP

Oramed Pharmaceuticals (ORMP)

Oramed Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ORMP
DateTimeSourceHeadlineSymbolCompany
04/02/201404:51PR Newswire (US)SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oramed Pharmaceuticals Inc. - ORMPNASDAQ:ORMPOramed Pharmaceuticals Inc
31/01/201403:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
30/01/201420:00PR Newswire (US)Oramed Announces Successful FDA Phase 2a Clinical Trial ResultsNASDAQ:ORMPOramed Pharmaceuticals Inc
28/01/201401:10PR Newswire (US)Oramed to Announce Results of its Phase 2a Clinical Trial for Oral Insulin on January 30th at the Tel Aviv Stock ExchangeNASDAQ:ORMPOramed Pharmaceuticals Inc
03/01/201400:20PR Newswire (US)Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of ProteinsNASDAQ:ORMPOramed Pharmaceuticals Inc
25/12/201313:12PR Newswire (US)Oramed to Raise $15,800,000 in Registered Direct OfferingNASDAQ:ORMPOramed Pharmaceuticals Inc
20/12/201323:30PR Newswire (US)Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 DiabetesNASDAQ:ORMPOramed Pharmaceuticals Inc
11/12/201302:37PR Newswire (US)Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in IsraelNASDAQ:ORMPOramed Pharmaceuticals Inc
20/11/201301:57PR Newswire (US)Oramed Receives Patent in the European Union for the Oral Delivery of InsulinNASDAQ:ORMPOramed Pharmaceuticals Inc
13/11/201302:12PR Newswire (US)Oramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin CapsuleNASDAQ:ORMPOramed Pharmaceuticals Inc
10/10/201308:23Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ORMPOramed Pharmaceuticals Inc
04/10/201301:13PR Newswire (US)Oramed Granted Patents in Japan and Canada for its PODâ„¢ Technology for the Oral Delivery of ProteinsNASDAQ:ORMPOramed Pharmaceuticals Inc
25/09/201322:10PR Newswire (US)Oramed to Participate in Barclays' Israel Biotech Corporate Day in Zurich on September 30, 2013NASDAQ:ORMPOramed Pharmaceuticals Inc
17/09/201322:10PR Newswire (US)Oramed's Platform Technology in Oral Delivery of Proteins Receives Patent in RussiaNASDAQ:ORMPOramed Pharmaceuticals Inc
10/09/201322:10PR Newswire (US)Oramed Granted Patent in China for its Platform Technology in Oral Delivery of ProteinsNASDAQ:ORMPOramed Pharmaceuticals Inc
03/09/201322:10PR Newswire (US)Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 DiabetesNASDAQ:ORMPOramed Pharmaceuticals Inc
23/08/201320:01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ORMPOramed Pharmaceuticals Inc
21/08/201322:10PR Newswire (US)Oramed Initiates Patient Recruitment for a New Clinical Trial in Israel of its Oral Insulin Drug ORMD-0801 in the Treatment o...NASDAQ:ORMPOramed Pharmaceuticals Inc
01/08/201320:49Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
30/07/201322:10PR Newswire (US)Oramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901NASDAQ:ORMPOramed Pharmaceuticals Inc
30/07/201306:47Edgar (US Regulatory)Post-effective Amendment (investment Company, Rule 485(b)) (485bpos)NASDAQ:ORMPOramed Pharmaceuticals Inc
30/07/201306:47Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ORMPOramed Pharmaceuticals Inc
19/07/201305:04Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ORMPOramed Pharmaceuticals Inc
19/07/201305:03Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
19/07/201305:03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ORMPOramed Pharmaceuticals Inc
19/07/201305:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ORMPOramed Pharmaceuticals Inc
19/07/201304:59Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ORMPOramed Pharmaceuticals Inc
18/07/201306:14Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ORMPOramed Pharmaceuticals Inc
17/07/201300:26Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:ORMPOramed Pharmaceuticals Inc
13/07/201305:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ORMPOramed Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ORMP

Your Recent History

Delayed Upgrade Clock